Seventeen of the complaints also name Eli Lilly and Co. competitor Novo Nordisk Inc. as a defendant and make similar allegations about its GLP-1 drug, Ozempic.
Attorney General Todd Rokita announced Monday that Indiana is expected to receive another $16.5 million as part of the latest multistate opioid settlement.
New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room manufacturing site for radiopharmaceutical cancer therapies.
Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.
Partnerships between telehealth companies and pharmaceutical giants Pfizer and Indianapolis-based Eli Lilly and Co. raise concerns about conflicts of interest and inappropriate prescribing, according to a Senate investigation released Thursday.
The idea could help the administration achieve one of President Donald Trump’s main health-care goals: ensuring foreign countries aren’t getting a better deal on drugs.
Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.
The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.
The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.
Most of the money would go to state and local governments to address the nation’s addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims.
Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months.
1Elevan Biopharmaceuticals plans to relocate to a vacant industrial building near Interstate 69 and East 121st Street, where it expects to build a workforce of at least 120 employees over the next decade.
Indiana Attorney General Todd Rokita said the agreement addresses the devastating impact of Purdue Pharma’s aggressive marketing of opioid products under the Sackler family’s ownership, which “fueled the worst drug crisis in U.S. history.”
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.
Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and sensory hyperexcitability disorders.
The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting.
The Danish pharmaceutical company, which competes heavily with Indianapolis-based Eli Lilly and Co. in the weight-loss market, is leaving by “mutual agreement” with the company’s board of directors.
Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors.
